Abstract: Sterilising immunity against HIV-1 infection, whilst ideal, appears an unrealistic vaccination goal in the short term. More achievable is slowing the progression to disease and decreasing transmission by mounting strong T cell and neutralising antibody responses to maintain low viral loads. However, in both acute and chronic infection, mutant virus is selected to escape both arms of the adaptive immune system. Each mutation away from wildtype virus likely incurs at least some reduction in replicative capacity ("fitness") of the virus. Rapid reversion to wildtype of some immune escape mutations upon transmission, suggests fitness costs may be significant. HIV-1 Envelope is unique in that it is subject to both neutralising antibody and cell-mediated immune responses. Although Envelope is variable between strains, considerable serial pressure and mutational escape from both neutralising antibody and cytotoxic T lymphocyte attack may result in impaired structure and function. This could ultimately be exploited in HIV vaccine design.
INTRODUCTION
Untreated, severe immunodeficiency causes death from opportunistic infections on average 10 years after initial HIV infection. However, spectacular damage is done to the immune system within the first 10-14 days of infection. Memory CD4+ T lymphocytes within the gut mucosa are exquisitely sensitive to infection and deletion during acute HIV infection [50] . In the well-studied SIV-macaque model of HIV infection, up to 60% of all gut memory CD4+ T cells were SIV-infected as early as 10 days post infection, and 4 days later, 80% of these cells were eliminated [54] . Host immune responses can partially control viremia in acute infection, although many immune responses select viral immune escape mutations [40, 65] . Understanding and modulating the early virological and immunological events set in motion by acute HIV-1 infection is likely to be critical for long term control of viremia and prevention of immunodeficiency without drug therapy [13, 39, 66] .
ADAPTIVE IMMUNE CONTROL OF HIV-1
Immediately following the exponential growth of virus during acute infection, an approximate 2 log 10 reduction in viral levels typically ensues [22] (Fig. 1) .
T lymphocytes (both CD4+ T helper cells and CD8+ cytotoxic T lymphocytes (CTL)) and neutralising antibodies (NAb) are now well recognised as the critical adaptive immune responses partially controlling HIV. HIV-1 specific CD8+ CTL responses, rather than NAb responses, correlate with falls in acute viremia prior to seroconversion [9, 47] . CTL responses during early HIV infection, particularly to the HIV-1 Envelope (Env) protein, have been associated with a slower progression of disease [57] . A contrasting view on this phenomenon suggests that the viral decrease immediately following acute HIV infection could be a result *Address correspondence to this author at the Department of Microbiology and Immunology, University of Melbourne, 3010, Australia; Tel: 61383440073; Fax: 61383443846; E-mail: vpeut@pgrad.unimelb.edu.au of the massive reduction of infectable cellular targets, rather than the immune response [63] . However, CD8+ T cell depletion of SIV-infected macaques results in a brisk increase in SIV viremia [41, 74] , suggesting a direct role for CD8+ T cells. Activated CD8+ T cells also release many soluble factors, shown to suppress HIV-1 activity, including chemokines which bind CCR5 and inhibit HIV-1 entry [19] . The relative roles of direct cytolytic killing verses release of soluble factors by CD8+ T cells in the control of viremia is controversial [24] , but recent analysis suggest indirect mechanisms may predominate [2] .
Virus-specific CD4+ T helper cell responses are intimately linked with the development of CD8+ responses [43] . Unfortunately, activated memory CD4+ T cells are preferentially infected, and ultimately destroyed by HIV-1. HIV-1 specific T cells are even more readily infected by HIV-1 than those not specific for the virus [27] . This process undermines the long-term immune control of this virus [72] .
Several human and non-human primate passive transfer studies have corroborated the importance of NAb to HIV-1 Env [37, 53, 55, 80] . Trkola and colleagues recently showed that IV administration of a cocktail of NAb to HIV-1 infected patients after cessation of antiretroviral therapy (ART) resulted in a slower rebound of viremia in a subset of patients [79] .
Antibody-dependent cellular cytotoxicity (ADCC) activity has also been linked to control of SIV in macaques [34] . There is also in vitro evidence in samples from HIVinfected humans that ADCC activity could have strong antiviral activity [31] . Mutational escape from Env ADCC epitopes has yet to be addressed, but it is well established that NK cells are the main effector cells in ADCC [1] and that NK cell-mediated ADCC is dysfunctional in HIV patients [28] .
IMMUNE ESCAPE
HIV-1 employs several methods to avoid detection by the human immune system. The HIV-1 regulatory protein Nef, not only hinders MHC-I progress towards the cell surface and recognition by CTL, but also results in internalisation and endosomal degradation of many MHC-I molecules [21, 75] . MHC class I deficiency should lead to targeting by NK cells, however, HIV-1 allows normal expression of HLA-C and HLA-E which inhibits NK cells [20, 61] .
Mutational escape from T cell immunity in HIV was first demonstrated in 1991 [65] . With an unreliable reverse transcriptase and incompetent repair mechanisms [12] , the high rate of HIV-1 replication provides numerous opportunities for the Darwinian selection of valuable mutations [5] . High rates of genetic recombination between strains and subtypes of HIV-1 compound problems of immune escape [17, 49] . CD8+ T cell escape probably accounts for a considerable proportion, if not most of all viral diversity [4, 56] .
Numerous studies have shown that CTL escape occurs at dominant T cell epitopes derived from Env [10, 42] and all other HIV-1 proteins. Indeed, escape is considered a "hallmark of acute infection" [59] . Typical T cell escape mutations cause the presented epitope to be sufficiently different as to be no longer bound by the presenting MHC class I, or recognisable by the TCR of the specific CTL [69] .
Escape from CD4+ T cells has been shown in mice infected with the RNA virus lymphocytic choriomeningitis virus [18] , suggested by a "directional change" in viral sequence [64] . This phenomenon of CD4+ T cell escape has not yet been described in HIV models, despite numerous reports of SIV and HIV-specific CD4 T cells [8, 73] . A recent study found that viral escape was not linked to poor HIV-1 Env-specific Th responses in the patients studied [52] . Two reasons might account for this. Firstly, the CD4+ response may not be effective. This appears unlikely, as the potent CD8+ immune response usually mounted in acute infection requires CD4+ T cell help [43] . Secondly, the CD4+ T cells are not generally cytolytic; mounting direct, selective pressure. Consequently, it may not be necessary for the virus to mutate at CD4 T cell epitopes having already evaded the immune response through mutation at CD8 epitopes.
Env is unique among the HIV genes in being targeted by both NAb and T cell responses. Structural investigations of the surface Env protein gp120 have elicited 4 distinct faces: a non-neutralising and a neutralising face, a variable face and a silent face [48] . Changes are wrought in the Env depending on whether it is in its liganded or unliganded state. Refolding of gp120 on binding CD4 will present multiple, different antigenic molecules to a host's humoral immune system [16] . A major hope for a broadly effective NAb target would be antigens within the neutralising face [83] , but it, like the silent and variable faces is subject to an "evolving glycan shield", where selected mutations in Env-directed sugar packing prevent attachment by NAb [82] . Highlighting serial NAb escape at Env epitopes, in vivo studies have shown that sera from HIV infected subjects could neutralize past viral quasispecies, but not the concurrent or future variants of the virus [70] . The vast array of mutations HIV-1 Env incurs to keep ahead of these rapidly evolving NAb responses [70, 82] likely incurs at least modest, but serial fitness costs.
FITNESS COST OF VIRAL ESCAPE
There is a growing appreciation that immune pressure to mutate away from wildtype (WT) virus usually elicits an appreciable reduction in the comparative replicative capacity ("fitness") of the mutant virus. The fitness impact of mutations was first studied in detail following acquisition of drug resistant mutations [71] , many of which result in impaired fitness during in vitro competition assays, a delay in disease and reversion to WT sequence following withdrawal of drug pressure [58] . Viral escape is well documented from the popular nucleoside reverse Fig. (1) . Schematic diagram of partial control of viremia during acute HIV infection. Potential scenarios of the absence of effective immunity such as by CD8 T cell depletion [51] , and effective immune responses such as those that are not readily escaped during acute infection [38, 44] are shown by the dashed and dotted lines respectively. transcriptase inhibitor lamivudine [11] , but a consequent decrease in viral fitness has now also been established [81] .
Heterosexual transmission is largely responsible for the AIDS pandemic, yet actual transmission rates per act of sexual intercourse are low [67] . Subtype C HIV-1 strains transmitted during acute infection can have shorter variable regions in Env [25] . This should reduce the number of Nlinked glycosylation sites and enable easier access to receptor sites on the recipient's immune cells. However, this also renders the virus highly sensitive to NAb. Contrasting results were found in a study of homosexual transmission of HIV-1 subtype B, where transmission of a viral quasispecies that was more susceptible to the recipient's NAb occurred infrequently [33] . Whether this contrast is due to mode of transmission, the subtype of the virus or the diversity of quasispecies in the source is unclear [33] . The "transmission" of neutralisation sensitive HIV-1 subtype C strains [25] could also be interpreted as reversion of NAb escape variants to WT during acute infection (as in Fig. 2C where MHC matching is not relevant since this is a humoral response). Note that reversion of T cell escape mutations can be very rapid -completed by 14 days post infection [30] , well before the vast majority of HIV-1 infected subjects are identified and have samples taken for genetic analysis. Thus the identified "transmitted" strain may contain substantial numbers of reversion mutations of the escaped virus.
Recently, the costs of T cell and possibly NAb immune escape have become clearer. CD8+ T cell immune escape variants generally revert to WT upon passage to a new host that cannot respond to the same epitope, both in macaques with SIV/SHIV infection [30, 32] and humans with HIV-1 infection [3] . A reduced SIV viral load occurs in pigtail macaques which respond to the immunodominant Gag epitope KP9 [77] , even in animals where the virus has escaped this epitope [78] . SIV/SHIV escape mutants can eventually cause disease, however this is likely to take longer in comparison to WT virus infection effectively controlled by CTL [7] .
It has been relatively difficult until recently to quantify the fitness impact of T cell escape mutations in vivo. However, the impact of viral mutations can be calculated by the rate of reversion back to WT in vivo, in the absence of CTL pressure, when virus is transmitted between hosts not sharing MHC alleles [30] (Fig. 2B) . Those mutations that prove more costly in terms of viral replication should revert rapidly back to WT when immune pressure is lifted, whilst those with minimal impact will revert slowly [45] . This is a simplistic view of T cell escape mutations and their fitness cost, since any fitness reductions may be alleviated to some extent by compensatory mutations elsewhere in the genome [35] . Interestingly, transient reversion and re-escape is likely to ensue when escape mutant (EM) virus is transmitted to a host that eventually generates a T cell response at this epitope [45] (Fig. 2C) .
CONSTRAINTS ON IMMUNE ESCAPE
Reversion of immune escape variants to WT upon transmission, in the absence of immune pressure, implies a fitness cost of the immune escape mutation. That is, the amino acid change made by the escape mutation results in some functional deficit to the protein, commonly through the resultant change in secondary structure [76] . However, HIV is not infinitely malleable. Indeed, escape from most T cell responses follow highly defined escape motifs, even at the nucleotide level [46] . This suggests that the common escape motifs result in the best balance of high immune escape and low fitness cost. Fig. (2) . A. Emergence of T cell escape mutant (EM) variant as a result of the CD8+ T cell response during acute infection with WT virus. The EM virus dominates subsequent virus population. B. Transmission of EM virus to an MHC-mismatched recipient which cannot generate a T cell response to the relevant epitope results in reversion to WT and disappearance of the EM population. C. Transmission of EM virus to an MHC-matched recipient which can generate a T cell response to the WT epitope. Since no HIVspecific T cells are present at the time of transmission, initial reversion of the EM virus to the WT occurs (similar to B). However, as a T cell response is generated, re-escape to EM virus occurs (as in A).
As more escape mutations are acquired, a progressive loss of fitness would be expected to ensue, assuming only partial compensation of the fitness deficit incurred by the initial mutations. However, only a limited number of T cell epitopes are recognised by any one host. Hosts generating T cell responses that recognise broader arrays of epitopes, particularly if some are targeted at conserved regions, are likely to impart a greater fitness cost to the virus as escape ensues at most, or all epitopes. This is broadly supported by the finding that subjects with greater numbers of different MHC class I alleles (heterozygous at each of the HLA-A, B and C loci), control HIV viremia more effectively than homozygotes [15] . Only rare cases have been reported where viremia is controlled by a narrowly focused CD8 T cell response [29] .
ENVELOPE AS A TARGET FOR BOTH T CELLS AND NAb
Env is a highly variable protein, therefore intuitively not an attractive target for generating T cell immunity. Unexpectedly perhaps, several macaque studies have now demonstrated a significant additional benefit in control of SIV or SHIV viremia when Env genes are added to T cellbased vaccine regimes [6, 26, 68] . This occurs despite any clear induction of NAb by the vaccines to the challenge virus. Our own recent studies have also demonstrated significant protection from B clade Env-expressing T cell based DNA/fowlpox virus (FPV) prime/boost regimes despite a heterologous B clade SHIV challenge [23] . This occurred despite the Env genes being deleted in the middle third of the protein so no NAb could be induced prior to challenge. Interestingly, this level of protection was substantially less when an AE Env gene was expressed by the DNA/FPV vaccine, and the same B clade SHIV challenge (Kent et al. unpublished data) . Only modest crosstype recognition of Env-specific T cell epitopes (2 of 10 Env epitopes were recognised by both subtype B and AE derived peptides) was generated in that study (Peut et al. unpublished data) . Further, Musey et al. showed that Env-specific CTL during acute HIV-1 infection correlated with reduced viral load [57] . Taken together, these studies suggest Env-specific T cells may be useful despite the heterogeneity of this protein.
In the successful macaque studies cited above, Env expressing vaccines produced significant (and likely helpful) levels of NAb to the heterologous challenge viruses. This response was generated early after challenge and was much higher and broader than in control animals. The ability to generate these NAb reflects, in part, the lack of significant, early immunosuppression of these primarily CXCR4-utilising SHIV challenges in the vaccines. None-the-less, the virus now faces dual pressure at the Env protein from both T cells and NAb.
The forces of both CD8+ T cells and NAb during acute infection are highly likely to generate immune escape variants. Escape from Env-specific CD8 T cells in humans has previously been documented [10, 42] and we have recently identified common escape mutations at Env-specific CD8 T cell epitopes in vaccinated and SHIV-challenged pigtailed macaques (Peut et al. unpublished data). Defining escape motifs from particular NAb responses has been less well studied, although it undoubtedly exists [70, 82] . Trkola and colleagues showed that infusion of defined, broadly reactive NAb resulted in biological NAb escape in some subjects [79] . Haigwood and colleagues recently reported the evolution of N-linked glycosylation mutants [36] .
For adequate function, Env must be a highly conformational, flexible protein. We speculate that there are likely to be significant constraints on the ability of Env to mutate away from broadly targeted CD8+ T cell and NAb responses and still maintain functional integrity of the protein. The fitness deficit incurred with mutations away from both parts of the adaptive immune response may partially explain the encouraging outcomes associated with Env-expressing T cell -based S/HIV vaccine regimes.
Ultimately, using knowledge on which particular sets of Env-specific T cells and NAb impart the greatest "fitness barrier" to overcome if escape ensues, could have a significant effect on rational HIV vaccine design. We are currently grappling with defining both T cell and NAb escape in macaques that control SIV or SHIV replication well. Some of these highly escaped viruses are now being reintroduced to naïve macaques to study their rate of reversion to WT, and thereby ameliorate their in vivo fitness cost [45] . Such data should guide the selection of antigens to induce immune responses which incur the highest fitness cost of escape.
CONCLUSION
With the remarkable genetic plasticity of HIV-1, it is possible that an untreated patient has every possible viral genome circulating through their body [60] . There are, however, structural and functional constraints to mutation levels in response to immune pressure [4] . Compensatory mutations can partially ameliorate these constraints [44, 62] , but may incur their own fitness costs. We hypothesise that as the virus mutates away from immune responses, it incurs a fitness cost that will, at least in some subjects, slow the course of the disease. Env is the only HIV-1 protein targeted by both NAb and cellular arms of the adaptive immune system. Focusing research on Env, its structural biology, function and NAb interactions [14] as well as the epitopes presented to effector T cells could favourably influence vaccine design. 
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